ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeTo evaluate HRDetect, a mutational signature-based algorithm, for prognostic utility in tubo-ovarian carcinoma and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis can refine genomic classification beyond the traditional homologous recombination-deficient versus homologous recombination-proficient framework. EXPERIMENTAL
designWGS was performed on matched tumor-normal pairs from 185 patients with advanced-stage tubo-ovarian carcinoma from the University of Washington (UW) cohort. HRDetect scores were calculated using substitution signatures, RS, microhomology-mediated deletions, and global loss of heterozygosity. An independent validation cohort (ARIEL2, n = 77) of platinum-sensitive tubo-ovarian carcinoma treated with rucaparib was analyzed to correlate HRDetect with PARP inhibitor (PARPi) response. RS analysis and unsupervised hierarchical clustering were employed to delineate genomic subgroups.
resultsIn the UW cohort, 51.4% of cases were classified as HRDetect-high and had significantly prolonged median overall survival versus others [6.2 vs. 4.1 years; hazard ratio (HR), 0.6; 95% confidence interval (CI), 0.41-0.87; P = 0.007]. Furthermore, 48.4% of HRDetect-high tumors harbored BRCA1/2 mutations or BRCA1 promoter methylation, whereas 22.1% lacked BRCA1/2 alterations. A substantial fraction (23.2%) fell into an HRDetect-intermediate category, highlighting greater genomic heterogeneity than currently appreciated. RS profiling uncovered 11 genomic clusters, with specific RS profiles (RS1, RS14, and RS18) correlating with poor survival. In ARIEL2, HRDetect-high tumors showed better PARPi responses, with improved progression-free survival (11.1 vs. 7.1 months; HR, 0.44; 95% CI, 0.26-0.74; P = 0.03) and response rates (54% vs. 22.5%).
conclusionsHRDetect predicts survival and sensitivity to PARPi in tubo-ovarian carcinoma. Combined with RS-based clustering, it reveals unappreciated genomic heterogeneity and supports a nuanced stratification framework to improve precision oncology in tubo-ovarian carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.